** Shares of vaccine developer HilleVax rise ~14% to $2.13 premarket
** HLVX to lay of about 28 employees, or about 70% of its workforce, to reduce operating costs, co said on Thursday
** Co says remaining team will focus on developing norovirus vaccine candidates, HIL-214 and HIL-216
** Co estimates that it will incur charges associated with the workforce reduction of about $6.1 mln
** As of Dec. 31, 2023, HLVX had 90 full-time employees - SEC filling
** Earlier this year, HLVX laid off about 41 employees
** As of last close, stock has fallen 88.4% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Comments